20% of adults and 40% of children will die before receiving an organ.
EVOSS™ offers a solution to this problem by enabling utilization of a significant portion of the pool of currently unutilized organs
While the number of organ transplants in North America has remained relatively static at around 30,000 per year, the number of people added to the transplant wait list continues to grow. There are currently more than 125,000 people on transplant wait lists for heart and lungs in North America alone.
The root of this problem lies in utilization – less than 25% of donated organs are deemed suitable for transplantation. This is further exacerbated by the current standard of care for organ preservation – cold storage – which limits preservation time, transport distance and causes cold ischemic injury. The current method for heart and lungs preservation, known as cold static storage, results in progressive tissue damage and gives the organ a short 6 hour window of opportunity for organ viability.
Dr. Darren Freed and Dr. Jayan Nagendran have developed an innovative transplant technology, Ex-Vivo Organ Support System (EVOSS™). EVOSS™ offers a solution to this problem by enabling utilization of a significant portion of the pool of currently unutilized organs.
Learn more about EVOSS